Paper2013113
Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Schwendener RA and 3 others. Cancer Chemother Pharmacol, 1991. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. Papers, record 2013113. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2013113
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Mitoxantrone | Major topic |
| Animals | |
| Bone Marrow | |
| Drug Carriers | |
| Female | |
| Half-Life | |
| Humans | |
| Leukemia L1210 | |
| Liposomes | |
| Male | |
| Mammary Neoplasms, Experimental | |
| Membranes | |
| Mice | |
| Mice, Inbred ICR | |
| Mice, Inbred Strains | |
| Mice, Nude | |
| Neoplasm Transplantation | |
| Neoplasms, Experimental | |
| Phosphatidic Acids | |
| Tissue Distribution |
Source PubMed
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 3473685 | High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. | Semin Oncol | 1987 | https://conductscience.org/library/papers/3473685 | PubMed |
| 2 | 3165047 | Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. | Cancer | 1988 | https://conductscience.org/library/papers/3165047 | PubMed |
| 3 | 6700415 | [Growth of human cancers in the thymus aplastic nude mouse]. | Med Welt | 1984 | https://conductscience.org/library/papers/6700415 | PubMed |
| 4 | 2491964 | Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2491964 | PubMed |
| 5 | 6733844 | Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6733844 | PubMed |
| 6 | 3470546 | Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. | J Natl Cancer Inst | 1987 | https://conductscience.org/library/papers/3470546 | PubMed |
| 7 | 2543512 | Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study. | Cancer Chemother Pharmacol | 1989 | https://conductscience.org/library/papers/2543512 | PubMed |
| 8 | 7225141 | Interactions of a new antitumor agent, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]-ethyl]amino]-9,10-anthracenedione, with nucleic acids. | Biochem Pharmacol | 1981 | https://conductscience.org/library/papers/7225141 | PubMed |
| 9 | 3412115 | Membrane lipid alteration: effect on cellular uptake of mitoxantrone. | Lipids | 1988 | https://conductscience.org/library/papers/3412115 | PubMed |
| 10 | 4019117 | Mitoxantrone as a first-line treatment of advanced breast cancer. | Invest New Drugs | 1985 | https://conductscience.org/library/papers/4019117 | PubMed |
| 11 | 6690066 | Mitoxantrone: an active new agent in the treatment of advanced breast cancer. | Cancer Chemother Pharmacol | 1984 | https://conductscience.org/library/papers/6690066 | PubMed |
| 12 | 3370735 | Selectivity of the anthracyclines for negatively charged model membranes: role of the amino group. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3370735 | PubMed |
| 13 | 2939941 | The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer. | Cancer Drug Deliv | 1986 | https://conductscience.org/library/papers/2939941 | PubMed |
| 14 | 3521429 | Mitoxantrone: a new anticancer drug with significant clinical activity. | Ann Intern Med | 1986 | https://conductscience.org/library/papers/3521429 | PubMed |
| 15 | 427798 | Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. | Cancer Res | 1979 | https://conductscience.org/library/papers/427798 | PubMed |
| 16 | 6347376 | Mitoxantrone (novantrone): a review of experimental and early clinical studies. | Cancer Treat Rev | 1983 | https://conductscience.org/library/papers/6347376 | PubMed |
| 17 | 2974073 | The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes. | J Microencapsul | 1988 | https://conductscience.org/library/papers/2974073 | PubMed |
| 18 | 3413128 | Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. | Proc Natl Acad Sci U S A | 1988 | https://conductscience.org/library/papers/3413128 | PubMed |
| 19 | 3768370 | Liposome-mediated delivery of pteridine antifolates to cells in vitro: potency of methotrexate, and its alpha and gamma substituents. | Biochim Biophys Acta | 1986 | https://conductscience.org/library/papers/3768370 | PubMed |
| 20 | 3370737 | Liposomes as drug carrier system for cis-diamminedichloroplatinum (II). II. Antitumor activity in vivo, induction of drug resistance, nephrotoxicity and Pt distribution. | Cancer Chemother Pharmacol | 1988 | https://conductscience.org/library/papers/3370737 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31236772 | Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. | Pharm Res | 2019 | https://conductscience.org/library/papers/31236772 | PubMed |
| 9083333 | Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9083333 | PubMed |
| 9010021 | Plasma clearance, biodistribution and therapeutic properties of mitoxantrone encapsulated in conventional and sterically stabilized liposomes after intravenous administration in BDF1 mice. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9010021 | PubMed |
| 7880728 | Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7880728 | PubMed |
| 7506649 | Liposomes as carriers of cancer chemotherapy. Current status and future prospects. | Drugs | 1993 | https://conductscience.org/library/papers/7506649 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2013113
GET https://conductscience.org/api/papers/v1/2013113/references?page=2